Literature DB >> 28679028

Hepatic iron is the major determinant of serum ferritin in NAFLD patients.

John D Ryan1, Andrew E Armitage2, Jeremy F Cobbold1, Rajarshi Banerjee3, Oscar Borsani4, Paola Dongiovanni4, Stefan Neubauer5, Reza Morovat6, Lai Mun Wang1, Sant-Rayn Pasricha2, Silvia Fargion4, Jane Collier1, Eleanor Barnes1, Hal Drakesmith2, Luca Valenti4, Michael Pavlides1,5.   

Abstract

BACKGROUND AND AIMS: Elevated serum ferritin is common in NAFLD, and is associated with more advanced disease and increased mortality. Hyperferritinaemia in NAFLD is often attributed to inflammation, while in other conditions ferritin closely reflects body iron stores. The aim of this study was to clarify the underlying cause of hyperferritinaemia in NAFLD.
METHODS: Ferritin levels were examined with markers of iron status, inflammation and liver injury across the clinical spectrum of NAFLD using blood, tissue and magnetic resonance (MR) imaging. A separate larger group of NAFLD patients with hepatic iron staining and quantification were used for validation.
RESULTS: Serum ferritin correlated closely with the iron regulatory hormone hepcidin, and liver iron levels determined by MR. Furthermore, ferritin levels reflected lower serum adiponectin, a marker of insulin resistance, and liver fat, but not cytokine or CRP levels. Ferritin levels differed according to fibrosis stage, increasing from early to moderate disease, and declining in cirrhosis. A similar pattern was found in the validation cohort of NAFLD patients, where ferritin levels were highest in those with macrophage iron deposition. Multivariate analysis revealed liver iron and hepcidin levels as the major determinants of serum ferritin.
CONCLUSIONS: While hyperferritinaemia is associated with markers of liver injury and insulin resistance, serum hepcidin and hepatic iron are the strongest predictors of ferritin levels. These findings highlight the role of disordered iron homeostasis in the pathogenesis of NAFLD, suggesting that therapies aimed at correcting iron metabolism may be beneficial.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990MRIzzm321990; zzm321990NAFLDzzm321990; ferritin; hepcidin; liver iron

Mesh:

Substances:

Year:  2017        PMID: 28679028     DOI: 10.1111/liv.13513

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  20 in total

1.  Building bridges: PCSK7 as a NAFLD candidate gene connecting hepatic inflammation with hypertriglyceridemia.

Authors:  Rotonya M Carr; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2019-04-25       Impact factor: 5.922

2.  Adipose Tissue Transferrin and Insulin Resistance.

Authors:  Donald A McClain; Neeraj K Sharma; Shalini Jain; Alexandria Harrison; Lipika N Salaye; Mary E Comeau; Carl D Langefeld; Felipe R Lorenzo; Swapan K Das
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

3.  Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis.

Authors:  Hong Gao; Zhongmou Jin; Gautam Bandyopadhyay; Gaowei Wang; Dinghong Zhang; Karina Cunha E Rocha; Xiao Liu; Huayi Zhao; Tatiana Kisseleva; David A Brenner; Michael Karin; Wei Ying
Journal:  Cell Metab       Date:  2022-08-02       Impact factor: 31.373

4.  Heme Oxygenase Induction Suppresses Hepatic Hepcidin and Rescues Ferroportin and Ferritin Expression in Obese Mice.

Authors:  Nitin Puri; Yevgeniy Arefiev; Robert Chao; David Sacerdoti; Hibba Chaudry; Alexandra Nichols; Krithika Srikanthan; Athar Nawab; Dana Sharma; Vishal Hari Lakhani; Rebecca Klug; Komal Sodhi; Stephen J Peterson
Journal:  J Nutr Metab       Date:  2017-09-14

5.  Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease.

Authors:  Joel Marmur; Soheir Beshara; Gösta Eggertsen; Liselotte Onelöv; Nils Albiin; Olof Danielsson; Rolf Hultcrantz; Per Stål
Journal:  BMC Gastroenterol       Date:  2018-06-05       Impact factor: 3.067

6.  Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease.

Authors:  Laurence Britton; Kim Bridle; Janske Reiling; Nishreen Santrampurwala; Leesa Wockner; Helena Ching; Katherine Stuart; V Nathan Subramaniam; Gary Jeffrey; Tim St Pierre; Michael House; Joel Gummer; Robert Trengove; John Olynyk; Darrell Crawford; Leon Adams
Journal:  Hepatol Commun       Date:  2018-04-27

Review 7.  Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.

Authors:  Driton Vela
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

Review 8.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 9.  From Environment to Genome and Back: A Lesson from HFE Mutations.

Authors:  Raffaela Rametta; Marica Meroni; Paola Dongiovanni
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

10.  Liver cT1 decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus.

Authors:  Eleanor Barnes; Michael Pavlides; Arjun N A Jayaswal; Christina Levick; Jane Collier; Elizabeth M Tunnicliffe; Matthew D Kelly; Stefan Neubauer
Journal:  Abdom Radiol (NY)       Date:  2020-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.